Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Hohaus

Showing results (41-50 of 48) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 48 results.
British Journal of Cancer|October 19, 2006
Reduced BRCA1 expression due to promoter hypermethylation in therapy-related acute myeloid leukaemiaA Scardocci, F Guidi, F D'Alo', et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 26, 2009
Cell-free circulating DNA in Hodgkin's and non-Hodgkin's lymphomasS Hohaus, M Giachelia, G Massini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 15, 2007
Polymorphism in cytokine genes as prognostic markers in Hodgkin's lymphomaS Hohaus, M Giachelia, A Di Febo, et al.
British Journal of Cancer|April 3, 1999
Stage III and oestrogen receptor negativity are associated with poor prognosis after adjuvant high-dose therapy in high-risk breast cancerS Hohaus, L Funk, S Martin, et al.
Neurology|February 25, 2011
Risk of acute promyelocytic leukemia in multiple sclerosis: coding variants of DNA repair genesS K Hasan, F Buttari, T Ottone, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 1, 1996
Localization of aspergillosis to the central nervous system among patients with acute leukemia: report of 14 cases. Gruppo Italiano Malattie Ematologiche dell'Adulto Infection ProgramL Pagano, P Ricci, M Montillo, et al.
Frontiers in Oncology|March 4, 2026
Siltuximab as a first-line therapy for idiopathic multicentric Castleman disease: a retrospective analysis based on the SiMuLa study of the Italian regional networkS Pelliccia, A Di Rocco, G Palumbo, et al.
Frontiers in Oncology|March 27, 2026
Correction: Siltuximab as a first-line therapy for idiopathic multicentric Castleman disease: a retrospective analysis based on the SiMuLa study of the Italian regional networkS Pelliccia, A Di Rocco, G Palumbo, et al.
Pageof 5

Showing results (41-50 of 48) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 48 results.
British Journal of Cancer|October 19, 2006
Reduced BRCA1 expression due to promoter hypermethylation in therapy-related acute myeloid leukaemiaA Scardocci, F Guidi, F D'Alo', et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 26, 2009
Cell-free circulating DNA in Hodgkin's and non-Hodgkin's lymphomasS Hohaus, M Giachelia, G Massini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 15, 2007
Polymorphism in cytokine genes as prognostic markers in Hodgkin's lymphomaS Hohaus, M Giachelia, A Di Febo, et al.
British Journal of Cancer|April 3, 1999
Stage III and oestrogen receptor negativity are associated with poor prognosis after adjuvant high-dose therapy in high-risk breast cancerS Hohaus, L Funk, S Martin, et al.
Neurology|February 25, 2011
Risk of acute promyelocytic leukemia in multiple sclerosis: coding variants of DNA repair genesS K Hasan, F Buttari, T Ottone, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 1, 1996
Localization of aspergillosis to the central nervous system among patients with acute leukemia: report of 14 cases. Gruppo Italiano Malattie Ematologiche dell'Adulto Infection ProgramL Pagano, P Ricci, M Montillo, et al.
Frontiers in Oncology|March 4, 2026
Siltuximab as a first-line therapy for idiopathic multicentric Castleman disease: a retrospective analysis based on the SiMuLa study of the Italian regional networkS Pelliccia, A Di Rocco, G Palumbo, et al.
Frontiers in Oncology|March 27, 2026
Correction: Siltuximab as a first-line therapy for idiopathic multicentric Castleman disease: a retrospective analysis based on the SiMuLa study of the Italian regional networkS Pelliccia, A Di Rocco, G Palumbo, et al.
Pageof 5